CSIMarket
 


Painreform Ltd  (PRFX)
Other Ticker:  
 
 

PRFX's Operating Income Growth by Quarter and Year

Painreform Ltd's Operating Income results by quarter and year




PRFX Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -8.87 -7.21 0.00 0.00
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -8.87 -7.21 0.00 0.00



PRFX Operating Income fourth quarter 2022 Y/Y Growth Comment
Painreform Ltd in the fourth quarter 2022 recorded Operating Loss of $ -8.87 millions.

According to the results reported in the fourth quarter 2022, Painreform Ltd achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Painreform Ltd' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2022.

Explain Operating Income growth


PRFX Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Painreform Ltd's fourth quarter 2022 Operating Income $ -8.87 millions PRFX's Income Statement
Painreform Ltd's fourth quarter 2021 Operating Income $ -7.21 millions Quarterly PRFX's Income Statement
New: More PRFX's historic Operating Income Growth >>


PRFX Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Painreform Ltd's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRFX's IV. Quarter Q/Q Operating Income Comment


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRFX's IV. Quarter Q/Q Operating Income Comment


Painreform Ltd's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative Operating Income 12 Months Ending $ -8.87 $ 0.00 $ 0.00 $ 0.00 $ -7.21
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Painreform Ltd' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Dec 31 2022 period.
The business is worsening as the cumulative Operating Loss is inflating from $ -7.21 millions in TTM ending quarter 0 and $ millions from the TTM period ending Dec 31 2021.

Painreform Ltd achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Painreform Ltd' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Dec 31 2022 period.
The results are detiriorating as the cumulative Operating Loss is getting bigger from $ -7.21 millions for the period from 0 to Dec 31 2021 and $ millions for the twelve months ending in the quarter Dec 31 2021 Letizia Colombo wrote.

Painreform Ltd achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
PRFX's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for PRFX's Competitors
Operating Income Growth for Painreform Ltd's Suppliers
Operating Income Growth for PRFX's Customers

You may also want to know
PRFX's Annual Growth Rates PRFX's Profitability Ratios PRFX's Asset Turnover Ratio PRFX's Dividend Growth
PRFX's Roe PRFX's Valuation Ratios PRFX's Financial Strength Ratios PRFX's Dividend Payout Ratio
PRFX's Roa PRFX's Inventory Turnover Ratio PRFX's Growth Rates PRFX's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2022
Medpace Holdings Inc 39.33%$ 39.333 millions
Merit Medical Systems Inc38.92%$ 38.916 millions
Iradimed Corporation36.80%$ 36.799 millions
Carlisle Companies Incorporated34.83%$ 34.834 millions
Pharming Group N v 34.45%$ 34.452 millions
Assertio Holdings inc 33.03%$ 33.029 millions
Repligen Corp30.47%$ 30.469 millions
Integer Holdings Corporation28.62%$ 28.615 millions
Biogen Inc 22.11%$ 22.109 millions
Edwards Lifesciences Corporation19.60%$ 19.605 millions
Electromed Inc 18.40%$ 18.401 millions
Inmode Ltd 18.14%$ 18.138 millions
Bio rad Laboratories Inc 17.95%$ 17.945 millions
Vertex Pharmaceuticals Inc17.75%$ 17.748 millions
Avantor Inc 17.66%$ 17.664 millions
Dr Reddy s Laboratories Limited17.17%$ 17.169 millions
Integra Lifesciences Holdings Corp16.52%$ 16.518 millions
Zoetis Inc 16.22%$ 16.216 millions
Alcon inc 15.86%$ 15.862 millions
Check cap Ltd 15.66%$ 15.663 millions
Global Cord Blood Corp15.49%$ 15.491 millions
Ensign Group Inc14.60%$ 14.604 millions
Idexx Laboratories Inc13.72%$ 13.724 millions
Glucotrack Inc 12.69%$ 12.688 millions
Resmed Inc 12.66%$ 12.658 millions
Mettler Toledo International Inc12.43%$ 12.428 millions
Option Care Health Inc 12.21%$ 12.210 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com